Efficacy of oral JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis
收藏官方服务：
资源简介：
Supplemental materials
补充材料
应用场景：
创建时间：
2024-01-31
相关数据集
Supplementary Material for: Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated With Improved Quality of Life Outcomes in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Background: Skin pain in atopic dermatitis (AD) increases with disease severity and is associated with substantial quality of life (QoL) burden. Objectives: To evaluate abrocitinib efficacy on skin p
DataCite Commons2023-12-11 更新80
Incidence of Conjunctivitis Adverse Event with Biologics for Atopic Dermatitis: A Systematic Review and Meta-analysis
Supplemental document
DataCite Commons2025-04-01 更新30
Supplementary Figure S2. Factors linked to percent scalp regrowth (model estimates).
This figure shows results from our adjusted regression model, which predicts how much hair regrowth patients achieved during each course of JAK inhibitor therapy. The model adjusts for factors includi
DataCite Commons2026-03-24 更新10
Supplementary Material for: Upadacitinib and Dupilumab Demonstrate Superior Efficacy in the Treatment of Adolescent Atopic Dermatitis: A Network Meta-Analysis
Objective: This systematic review and network meta-analysis aimed to compare and evaluate the efficacy and safety of five medications, dupilumab, tralokinumab, upadacitinib, baricitinib, and abrocitin
DataCite Commons2025-01-15 更新60
Full-text articles assessed for eligibility.
Background The newly approved biologics and Janus kinase inhibitors (JAKi) for pediatric atopic dermatitis (AD) offer additional options for clinical treatment. However, the efficacy and safety differ
NIAID Data Ecosystem20
